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I Summary: In 1988, inundated by the tedious work of validation of laboratory reports in a large hospital biochemis-
j try laboratory, we designed VALAB, a knowledge-based system specially dedicated to this iterative function.
Coping at first with a few biochemical tests, the program has been progressively expanded to forty-five common
chemical tests. Simultaneously some new rules have been introduced to "weight" the conclusion in different circum-
stances and rules taking into consideration some clinical data have also been written.
Moreover the program moved to other disciplines, pH and blood gases, haematology and coagulation. Accordingly
the evaluation protocol has been modified, incorporating a new step, the consensus decision of the pathologists,
operating within the initial protocol and based upon the various criteria of epidemiology.
These major changes and improvements have led us to check and describe again the performance of this updated
VALAB knowledge-based system.
Introduction
In large hospital laboratories that use high throughput
equipment, the task for human validation of final reports
is very important, in spite of the help provided by effi-
cient laboratory information systems. It is time consum-
ing and highly dependent on the skill and experience of
the supervisors. Therefore we decided in 1988 to use
"artificial intelligence" and to carry out a knowledge-
based system project to aid decision making and to per-
form an automated validation of data. The program was
first designed for an electrolyte profile (1) but it has
been rapidly expanded to handle 22 tests commonly run
in the clinical chemistry laboratory (2). Right now the
system is able to deal with 45 commonly used tests.
Simultaneously, new rules have been added to cope with
clinical data, the final decision is improved by "weigh-
ing" rules that are used in different clinical circum-
stances. Moreover, in addition to its use in, the Chemical
Pathology laboratory, the system has also been allocated
to other disciplines of laboratory medicine, Haematol-
ogy (3, 4) and Haemostaseology, where automated
equipment is also operated. When this occurred, the first
evaluation protocol (2) was modified and accordingly
also changed in Clinical Chemistry.
') This work was supported by grants from the Conseil Regional
de Midi Pyrenees and an award from the Societe Frangaise de Bio-
logie Clinique.
Since many amendments and improvements have been
introduced in the program, we have thought it would be
interesting to check again and report the performance




The knowledge-based system operates on a microcomputer IBM-
compatible PC (Compaq, Microdis, 31700 Blagnac, France) con-
taining an Intel 80386 or 80486 processor, 4 megabytes of RAM,
a 80-megabyte hard disk and Hercules or VGA graphics.
The software runs under MS-DOS and uses the generator (infer-
ence engine) KHEOPS (5) from the Laboratoire d'Automatique et
d'Analyse des Systemes, an institute of the Centre National de. la
Recherche Scientifique in France. KHEOPS uses forward chaining
as the reasoning process that is applied to the knowledge base re-
presented in the form of production rules. It is moreover able to
compile the rule base.
Methods
1. The various tests included in the knowledge base are listed in
tables 1 —2, covering Biochemistry, Haematology and Coagulation.
2. The production rules (more than 20 000) represent the knowl-
edge and are expressed in conditional (if-then) form. There are four
sets or rules:
(a) The ones representing the core of the system are devoted to
the various criteria selected to help decide whether to validate labo-
ratory data. VALAB actually uses the following information for
every patient data: acceptable limits, internal coherence between
analyte results which are physiologically related, delta check, ori-
gin of the sample, i.e. identification of the ward and the medical
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speciality, "Stat" analysis or not, out or in-patient, age, sex, com-
ments on the sample quality.
(b) Some rules (weighing rules) define dynamically acceptability
thresholds for each patient, as various trends for that patient are
noticed. This "qualitative reasoning" approach (5, 6) is a character-
istics of the second generation of knowledge-based systems. There
are weighing rules for instance to modify the acceptable, ranges in
various analyte values or in delta check acceptance.
(c) For each test some "negative" rules have been written in order
to restrict the validation of a normal value that would not be in
accordance with other data.
(d) particular rules cope with clinical or therapeutical data. They
are of major interest and must be developed in the future. An exam-
pie of these different rules is given in the Appendix.
All these rules are divided into 100 rule groups, each rule group
containing between 100 and 300 elementary rules which are related
Tab. 1 List of the chemical tests expertised by VALAB.
























































Tab. 2 List of the tests known by the expert system in haematol-
ogy and haemostaseology. Numerous other data, clinical, therapeu-
tic, morphological (erythrocytes) or plasma aspect (turbidity,


























Erythrocyte Sedimentation Rate (1 h)
Quick time (QT) or prothrombin time (PT)
International Normalized Ratio
Factor V
Factor VII + X
Factor II
Fibrinogen
Heparin level (unfractionated heparin)
Heparin level (low molecular mass heparin)
Activated partial thromboplastin time (APTT)
Thrombin clotting time (TCT)








Circulating anti coagulant CAC
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to a similar topic. An example of the strategic path used, e.g. for
the validation of a high aspartate aminotransferase value, is shown
in the Appendix.
Groups of rules are compiled, resulting in the construction of a
decision network that can be more rapidly processed than the rules
in their original form. This "pretreatment" of the internal represen-
tation of the knowledge base results in a total, inference time, which
varies for each report according to the number of data, but does
not exceed approximately 500 ms.
3. The evaluation protocol has been modified in order to introduce
a new step: the clinical chemists' and pathologists' consensus that
is the reference decision, with which either VALAB or every super-
visor decision will be compared. Four MDs with specialisation in
Chemical Pathology, two PhDs in pharmacy with specialisation in
Clinical Biochemistry and one PhD in Clinical Chemistry for the
laboratory of Clinical Chemistry and three MDs specialised in
Haematology for the Laboratory of Cellular Haematology and four
Clinical Pathologists in Haemostaseology were the human referees.
They had to check separately 338 patient reports in chemistry, 384
for pH and blood gases, 357 in haematology and 550 in haemosta-
seology. The control process was conducted along the epidemiolog-
ical method used to assess the sensitivity, specificity and predictive
values of a clinical symptom or a laboratory test. These values can
be calculated and compared between the knowledge-based system
and the human observers.
T(+) or true positive is defined as correctly stopping a wrong re-
port, T(—) or true negative is the validation of a correct report,
F(+) or false positive is the inappropriate rejection of a good report
and F(—) is badly accepting an incorrect report.
Review of the formulae shows that the emphasis must be largely
given to sensitivity and negative predictive value because they both
contain the unacceptable F(—).
Sensitivity
(proportion of rejected incoherent reports)
Specificity
(proportion of accepted coherent reports)
Positive predictive value
(proportion of incoherent reports
within the rejected ones)
Negative predictive value
(proportion of coherent reports
within the accepted ones) T(—) + F(—)
Furthermore, the system has also been submitted to a national
multicentric evaluation in five different laboratories, with 4 large
hospital laboratories of clinical chemistry and 1 big private labora-
tory of clinical pathology, representing a total of 19 referees.
4. Statistical data are available concerning the activity and the per-
formance of VALAB within the various laboratories of our hospi-
tal, with emphasis on results that are considered invalid, and which
must be viewed by the user along with the reasons given by the
system for the rejection.
Results
Data from the evaluation protocols and from the statisti-
cal activities are presented here.
1. Evaluation results
1.1 In Clinical Chemistry
In. this study 338 reports were included. The VALAB
decisions on the one hand and the human ones on the
other were both compared to the collegial decision, de-
fined as the consensus of the various supervisors. Data
are presented in table 3.
The various steps were
(a) to check first the 338 reports within a single period
of time for each of the seven supervisors in order to
consider the tiring effect of such a batch of results to
be validated. Fifty seven reports showed discrepancies
between the various supervisors and needed a search for
consensus which was easily met.
(b) Taking into account this consensus decision, two re-
ports accepted by VALAB but previously blocked by
the medical staif were thus accepted and therefore
2 F(— ) moved to 2 T(+); and twenty nine reports vali-
dated by the staff but firstly rejected by VALAB were
accepted by the system after some modifications in the
"weighing" rules, resulting in 29 F(+) becoming 29
T(-)
T(-)
(c) To improve the system performance again, we ad-
justed some upper limits and accordingly the VALAB
final decision was to reject four reports that were pre-
viously accepted, 4 F(-) becoming 4 T(+), and to ac-
cept nine cases rejected before the correction, 9 F(+)
moving to 9 T(— ).
With these last figures, sensitivity, specificity and pre-
dictive values were calculated again, showing a sensitiv-
ity of 100% and a negative predictive value of 100%;
these are the main values to consider because there is
F(— ) in their definition and we cannot accept a system
that inappropriately validates a wrong report.
T(+) + F(+) 1.2 Multicentric evaluation in Clinical Biochemistry
T(-) Data were collected under the same conditions within
the various selected laboratories at the national level.
VALAB was connected to different Laboratory Informa-
tion Systems and 1675 reports were examined.
The general conclusions are presented in table 4. In four
laboratories 38.5% of the reports accepted by the medi-
cal staff were also validated by VALAB, except in one
hospital laboratory dealing only with emergency testing
for very severe diseases and without previous results,
where the knowledge-based system accepted only 5% of
the 65% validated by the staff.
1.3 In haematology
The evaluation was performed by three clinical patholo-
gists on 357 reports randomly selected from the file of
reports needing a medical validation.
As in the clinical chemistry protocol, we performed the
first individual validation with the fatigue effect for hu-
man observation.
Some reports were then modified after consensus, fi-
nally producing VALAB's validation after amendment
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of some parameters for best fit with the pathologists'
consensus, which is considered as the ideal decision.
Between the first two steps, 89 reports produced variable
decisions amongst the three pathologists, necessitating a
consensus that was met easily, except for 5 reports
which were therefore withdrawn.
All these data are presented in table 5.
1.4 In haemostaseology
The evaluation was performed by four MDs who com-
pared their decision for 550 reports with that of the
VALAB. The same protocol was again used and gave
the following results:
111 reports needed a consensus, 94 lacking agreement
from the four pathologists, 17 being blocked by VALAB
and accepted by the medical staff (F(+)). There was no
F(—) in the expert system analysis.
After consensus decision and modification of some
parameters and some weighing data in VALAB's pro-
gram, the final calculation was excellent and gave 1.00
for sensitivity and negative predictive value, with no re-
sidual F(—).
1.5 pH and blood gases
The protocol covered 384 reports. During the first
VALAB's run we noted 7 F(-) and 71 F(+) most of
them, 51, due to a very high pO2 caused by oxygeno-
therapy. After the consensus meeting, the acceptable
limits for pO2 were modified and the 7 F(—) became
7 T(-). We decided also to ask the intensive care units
to mention the oxygen therapy on the request forms, this
Tab. 3 Epidemiological data for the three step evaluation of the (b) is the result obtained after consensus.
expert system VALAB in clinical biochemistry. (c) is the final decision of VALAB after modification of some






T(+) T(-) F(+) F(-) Accepted Rejected Sensitivity
127 165 39 7 172 166 0.947
57 reports among 338 needed a consensus between the seven supervisors
157 167 10 4 171 167 0.975












VALAB (c) 161 176 176 162 1.000 0.994 0.994 1.000
Tab. 4 Average of the data from 19 observers and from VALAB in a multicentric national evaluation
for the clinical chemistry program.
Sensitivity Specificity Positive PV Negative PV
Human data





















Tab. 5 Evaluation protocol in haematologic cytology.
(a) is the primary comparison between VALAB and three supervi-
sors.
(b) is the result obtained after consensus.
(c) is the final decision of VALAB after modification of some
parameters taking into consideration the consensus decision.
VALAB (a)
Staff No. 1 (a)
Staff No. 2 (a)
Staff No. 3 (a)
VALAB (b)
Staff No. 1 (b)
Staff No. 2 (b)
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information being therefore taken into consideration by
the knowledge-based system.
2. Statistical data concerning routine
operation
The three laboratories are using VALAB for a round the
clock service.
The reports submitted to the expert system are not iden-
tical, and they vary according to the discipline.
In Chemical Pathology the system examines only the
reports already blocked for any abnormality by the labo-
ratory information system and then stored in a special
file of reports to be validated. VALAB regularly ex-
plores this file and, according to its knowledge, either
rejects or validates the reports, which are, in this case,
immediately sent through the hospital network and
printed out. The remaining reports, with indication of
the reason for VALAB's rejection, are reviewed on the
screen of the laboratory information system by the medi-
cal staff.
In Haematology and Haemostaseology, entire reports
may be considered as abnormal by the laboratory infor-
mation system and thus VALAB has to expertise all the
data stored in the file.
An example of the activity of the knowledge-based sys-
tem during a relative quiet fortnight of July 1995 is
given in table 6.
Discussion
VALAB can be considered as a screening program dedi-
cated to the automated selection of reports needing a
human view, in order to either accept them as valid or
have them rerun or, mainly in Haematology or Haemo-
staseology, have them checked comprehensively with
dialogue with the physician.
It was most important, of course, to perform a very strict
evaluation to check the adequateness of VALAB ex-
pertise before the routine implementation of such an au-
tomated process. The method used for the evaluation
is derived from the epidemiological protocols. It gave
satisfactory results after addition of the consensus step,
which represents ideal decision from the medical point
of view.
We did not strictly follow Miller's proposal (8) who dis-
tinguished three levels of evaluation: evaluation of re-
search contribution, validation of knowledge and perfor-
mance, evaluation of the clinical efficacy of the opera-
tional system, because we limited our protocol to steps
2 and 3.
Actually, VALAB is not a clinical system to be used by
physicians for interpretation of laboratory data or sup-
port for diagnosis. It is rather a tool for senior clinical
chemists or pathologists remaining within the laboratory.
The only data available for evaluation of knowledge-
based systems are clinical data for the performance of
knowledge-based systems in their support of the inter-
pretation of laboratory findings (9). The strategy used
by Wyatt (10) is to answer the following questions:
i) is the system wanted and of good quality? (structure),
ii) is the system pleasant to use and does it reason appro-
priately? (reasoning process),
iii) does it say sensible things and draw valuable con-
clusions? (outcome); and the means of attaining this
goal are peer review and field trials.
We may consider that we have attained these objectives,
because VALAB is now spread over 35 European
laboratories, and because in our hospital, since 1988,
we have never had any question or argument from the
clinicians related to the patient reports validated by the
knowledge-based systems.
VALAB has now incorporated second generation con-
cepts (6, 7) and is able to weigh its decision according
to various predefined items.
The conditions of operation can be selected within the
main frame computer (laboratory information system) to
which the knowledge-based system is connected as an
analytical instrument; it can be as to examine either only
pathological reports or any report if the limits of normal-
ity are strictly narrowed.
VALAB has been designed as a tool for helping in the
tedious and iterative process of final medical validation,
and all the laboratories in Europe equipped with this
decision support program are using it for this task in the
clinical chemists' or pathologists' office. However, it is
obvious that many laboratories are limiting their valida-
tion at the bench, where they perform sophisticated pro-
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cess, using quality control, delta-check, mean of normals
appreciation as part of the technical validation. It is
therefore interesting to consider whether VALAB cannot
move to the bench, become embedded in the advanced
instrument workstation, and interface between high
throughput equipment and laboratory computer. Such a
development would seem imminent, particularly within
the "Openlabs" project of the European Community
(11, 12).
Whatever the location of VALAB within the laboratory,
one advantage must be emphasised, i.e. the improve·^
ment of turn around time due to a rapid check and often
validation of abnormal reports without waiting for a hu-
man decision. The application to various disciplines
where automated equipment provides a high volume of
data should also be mentioned, the program for immu-
noanalysis being presently under development.
Concerning the ethical problem, we have to remember
that VALAB is an aid to the decision maker, and is not
intended to supplant him (her); actually it represents a
cooperative effort of man and machine (13).
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Appendix
1. Examples of the different rules
a) Basic production rule (haemoglobin)
If there is a low value for haemoglobin,
If the patient is located within a surgical intensive care unit,
Then decrease the acceptability of this low haemoglobin by
30g/l.
b) Weighing correlation rule (serum calcium)
If there is a low value for calcaemia,
If there is a result for serum creatinine,
If the creatininaemia is higher than 150/300/500 μηηοΐ/ΐ,
Then increase the acceptability of this low calcaemia by —O.I/
-0.2/-0.3 mmol/1.
c) Negative rule (Quick time)
If there is an increase of Quick time higher than 8 seconds,
If there is a result for activated partial thromboplastin time,
If the increase of activated partial thromboplastin time is lower
than 3 seconds,
Then it is not possible to validate such a value for Quick time.
d) Clinical rule (pO2 in blood gases)
If there is any oxygen therapy,
If there is a result of pU2 higher than 100 mm Hg
Then it is possible to validate such an abnormal value of pO2.
2. Example of strategic reasoning pathway
If there is a very high value for serum aspartate aminotransferase
(e.g.; > 300 IU/1, 37 °C):
— Look for other data able to justify this value:
— Myocardial infarction context:
High or very high creatine kinase-MB, creatine kinase,
myoglobin, cardiologic intensive care unit location, clinical
information on myocardial infarction.
— Or hepatitis context:
Very high serum alanine aminotransferase, high or very
high conjugated bilirubin, infectious disease, high C-re-
active protein, digestive diseases ward location, clinical in-
formation on acute hepatitis.
— Or other context concerning liver or pancreatic disease.
- Or chemotherapy context.
- Control that there is no negative rule triggered to forbid the ac-
ceptability of such a value of serum aspartate amiriotransferase:
— e. g. very low result for serum alanine aminotransferase.
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TECHNICAL REPORT
A Multicentre Evaluation of Tumour Marker Determinations Using the
Automatic Enzymun-Test® Systems ES 300 and ES 600/700
Arie van Dalen1 and Anne-Christine Kesslet2
1 Department of Nuclear Medicine, Groene Hart Ziekenhuis, Bleuland location, Gouda, The Netherlands
2 Research Centre Tutzing, Boehringer Mannheim, Tutzing, Germany
Summary: A multicentre evaluation of the determination of carcinoembryonic antigen (CEA), the cancer antigens
CA 15-3, CA 19-9, CA 72-4 and CA 125 (II generation), the cytokeratin 19 marker Cyfra 21-1 and a-foetoprotein
(AFP) using the Enzymun-Test® System (ES 300 and ES 600/700) was performed in 23 laboratories. The tumour
. markers were measured in a total of 4266 human serum samples.
The intra-assay precision was less than 5% in 80% of all serum samples investigated and in 95% of the serum
samples at or above the cut-off level of the tumour markers. Inter-assay precision was less than 10% in 86% of the
marker determinations. The interlaboratory survey also showed high reproducibility for the determination of all the
tumour markers. In 3 laboratories the results of CA 15-3 in 283 serum samples were compared with the IRMA
method of CIS bio international. The regression coefficient, r, was 0.967. In 4 laboratories the results of CEA in
312 samples were compared with the results obtained on the IMx analyser. The regression coefficient, r, was 0.967.
In benign gynaecological diseases, CA 125 (II) was most frequently elevated in endometriosis. In gastrointestinal
diseases it was proven that CEA is still the marker with the highest sensitivity as compared with CA 19-9
and CA 72-2 (59% ^with healthy controls as the reference group and 44% with patients having benign
gastrointestinal disease as the control group). In pancreatic cancer CA 19-9 showed the highest sensitivity (78%
and 62% respectively). In gastric cancer the three markers did not show statistically different results. When
the gastric cancer patients were divided according to stage, CA 72-4 appeared to be more sensitive than CA
19-9 only in stage IV.
Introduction of automated apparatus. Special attention was given to
_, , t - . i_ · .__ ι j the second generation of the CA 125 determination andThe development of immunochemistry analysers made . ^,A -,/·» Λ ·., - , , , . ' , to the application of the new marker CA 72-4 m gastro-possible the automated determination of tumour mark- . . , __ , . . , ,._ .
_ t j , · . i_ j ι intestinal cancer. We also investigated differences in cut-ers. Recently, developments in immunoassay methodol- „.. . , , . , ° . 4 .. .• j κΤχ TT r. i off levels based on normals and on patients with relevantogy were reviewed (1). However, at present, the results .
f A. * +. *· - Α- Ά ι + benign diseases,of assays from some manufacturers for an individual tu-
mour marker vary considerably, as shown by external
quality assurance schemes (EQAS) in different countries .
• τ* ^ A^ m , · , _* ^τ-ο ΟΛΛ Material and Methodsin Europe (2—4). The analytical performance of ES 300
and ES 600 systems in smaller pilot studies has been Samples
reported (5, 6). The multicentre evaluation was performed in 23 laboratories. The
tumour markers were measured in 4266 human serum samples.
In this study we compare results for the determination These samples were obtained from local patients (N = 2170) dur-
of carcinoembryonic antigen (CEA), the cancer antigens in£ routine investigations in the institutes;
CA 15-3, CA 19-9, CA 724 and CA 125 (II), Cyfra 21- healthy subjects N = 1098;
1 (a marker of cytokeratiii 19) and α-foetoprotein (AFP) *™W pulmonary diseases N = 135;
, ™ ^~ , ™ ^wtiLwv ι - j benign gastrointestinal diseases Ν = 103;on the ES 300 and ES 600/700 analysers, m a study benign liver disease N = 85;
involving 23 laboratories. In addition to assessing the colon carcinoma at diagnosis N = 226;
technical performance of the analysers, comparative 8astric carcinoma at diagnosis N = 110;r . . . , . . , pancreatic carcinoma at diagnosis N = 63;
studies were earned out with routinely used assays, ovarian carcinoma patients N = 158 and
which were also performed manually or on other types benign gynaecological diseases N = 118.
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Assays
Enzymun-Test® CEA, CA 15-3, CA-19-9, CA 72-4, CA 125 II,
Cyfra 21-1 and AFP (Boehringer Mannheim Diagnostics, Ger-
many).
IMx system CEA, CA 19-9, CA 125 and AFP (Abbott Laborato-
ries, USA).
Cobas Core El A CA 19-9, CA 125 II and CEA (Hoffmann La
Roche, Switzerland).
ΑΙΑ 1200 CEA and AFP (Tosoh Corporation, USA).
ENZELSA CA 15-3, CA 19-9, CA 125 II and Cyfra 21-1 (CIS bio
international, France).
Stratus CEA (Baxter Diagnostics Inc., USA).
IRMA CA 19-9 and CA 72-4 (Centocor Diagnostics, USA).
All kits were taken from current production batches. The assays
were performed according to the manufacturer's instruction. All
laboratories were equipped with the fully automated Enzym-Test®
System ES 300 or ES 600/700.
Evaluation participants
France:
L. Deneux, Institut Curie, Paris
Italy:
G. Ai/no, Ospedale Molinette, Torino
F. Aregnati, Ospedale Riuniti, Jesi
S. Belloli, Universita degli Studi di Brescia, Brescia
A. Lofaro, Ospedale Civile "Lotti", Pisa
M. Onetto, Lab. di Patologia Clinica, Genova
P. Piantino, Ospedale Molinette, Torino
G. Ruggeri, Universita degli Studi di Brescia, Brescia
W. Taccone, Lab. Analisi Centrale, Avellino
G. Vignati, Ospedale Civile, Magenta
The Netherlands:
H. W. A. de Bruijn, Academisch Ziekenhuis, Groningen
A. van Dalen, Groene Hart Ziekenhuis, Gouda
J. Marrink, Academisch Ziekenhuis, Groningen
Portugal:
A. Carvalho dos Santos, Hospital Santo Antonio, Porto
M. Pereira de Melo, Hospital Santa Maria, Lisbon
Spain:
J. Alarco, Hospital Virgen del Pino, Las Palmas
C. Blanco Barros, Hospital de Getafe, Madrid
C. Cacero, Hospital Matemo Infantil, Malaga
C. Gonzales Valverde, Hospital Xeral de Vigo, Vigo
M C. Pastor, Hospital HNOS, Trias i Pujol, Badalona
Switzerland:
P. Borer and R. Keller, Klinik Barmelweid, Barmelweid
M. Caiezel, Kantonspital, Zug
H. Zihlmann, Kantonales Spital, Sursee.
Control material
Tumour marker controls level 1 and 2 produced by Boehringer
Mannheim Diagnostics. Interlaboratory study samples TM 2/92 (A
and B) of the German Society for Clinical Chemistry (Bonn, Ger-
many).
Evaluation protocol and statistical methods
All participants followed the protocol provided by Boehringer
Mannheim Research Centre.
Infra-assay precision
Native patient samples were analysed 10 times in one series. The
mean (x), the standard deviation (S. D.) and the coefficient of varia-
tion (CV%) were calculated.
inter-assay precision
The tumour marker controls were analysed as single determinations
in 3-5 different series. The mean, S.D. and CV% were calculated.
Interlaboratory survey
The samples TM 2/92 A and B were determined as one single
determination. The medium and scatter (given as the 16th and 84th
percentiles) of both samples A and B of all results were calculated
for each analyte.
Comparison studies
Patient samples were measured using the Boehringer Mannheim
enzyme immunoassay in parallel with the routine method of each
laboratory. Correlation was calculated using the method of
Passing & Bablok (7).
Reference values
Sera from healthy subjects (blood donors, hospital staff) were as-
sayed and the 95 and 99 percentiles of the results of each tumour
marker were calculated.
Sensitivity of CEA, CA 19-9 and CA 72-4
In gastric cancer, colorectal cancer and pancreatic cancer the sensi-
tivity was calculated at the 95th and 99th percentile of healthy
subjects. The same calculations were performed using the reference
values based on benign gastrointestinal disease. Significance was
calculated using Fisher's exact test.
Results
Intra-assay precision
Every institute performed the determinations on patient
samples containing different levels of markers. A target
coefficient of variation of less than 5% was reached in
80% of all serum samples including all tumour markers
(111 out of 139 = 80%). In serum samples starting at
the cut-off level or higher, a coefficient of variation of
less than 5% was confirmed in 72 out of 76 samples
(95%). All tumour markers showed the same pattern.
Examples are given in figures 1 and 2, for CA 19-9 and
Cyfra 21-1, respectively.
Inter-assay precision
The target coefficient of variation of less than 10% was
confirmed in 86% of all series (N = 120 for the total of
the two tumour marker control levels). The inter-assay
precision of the tumour marker control levels were de-
termined according to the evaluation protocol. In tables
1 and 2 the range of the inter-assay coefficient of varia-
tion of the different markers are represented together
with the number of participating laboratories. Also the
mean of the coefficient of variation in the different
laboratories was calculated. This was between 5.9% and
9.6% using the low control and between 3.9% and 7.2%
using high control. Also the number of laboratories with
a coefficient of variation of less than 10% is indicated.
The lowest mean CV% was found for AFP and the high-
est for CA 72-4 in both controls. > f
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Fig. 1 Enzymun-Test® CA 19-9. Intra-assay precision in human
sera as obtained in different institutes. The CV% of each run (y-
axis) is plotted against the mean concentration of the sample,
N = 23.
Fig. 2 Enzymun-Test® Cyfra 21-1. Intra-assay precision in hu-
man sera as obtained in different institutes. The CV% of each run
(y-axis) is plotted against the mean concentration of the sample,
N = 21.
[ Interlaboratory survey
The results for the assayed tumour markers in samples
A and B, which were provided by the German Society
for Clinical Chemistry (8), were compared with the re-
sults obtained in the 'German Ringversuch 1992' using
the Boehringer Mannheim Assays. The results are sum-
marized in tables 3a and b. An example is given for CA
19-9 in figure 3. The coefficient of variation was around
13% in the present study (13 laboratories) as compared
with around 17% in the 'German Ringversuch 1993' (47
laboratories).
Method comparison studies
In 29 cases results obtained with the ES 300 or the ES
600/700 were compared with those from one of the other
methods as performed routinely in the institute (see the
section Assays). As examples, the results are presented
for CA 15-3 (using the same antibodies) and for CEA
(using different antibodies). In three laboratories a total
of 283 serum samples were analysed with the CA 15-3
assay of Boehringer Mannheim and CIS bio interna-
tional. The resulting regression equation was: y = 1.180
χ - 2.620 (BM = y and CIS = x). The correlation coef-
Tab. 1 Tumour Marker Control low: The number of laboratories
(N) in which the inter-assay precision CVs (with min. and max.
ranges) were determined. The number of laboratories with a CV
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ficient (r) was 0.967 (p = < 1(T6). Figure 4 shows the
plotted results from 263 serum samples within the meas-
Tab. 3a Interlaboratory survey, TM 2/92 sample A (a), B (b). The
median and scatter given as the 16th and 84th percentiles of the
results from this study in comparison with the results obtained in
the "Ringversuch 1992".

















































































































Fig. 3 Interlaboratory survey Enzymun-Test® CA 19-9. A Youden
diagram with identification of the values obtained in this study ·
(13 laboratories) and the values from the Ringversuch 1992 ο with
Enzymun-Test® CA 19-9.
uring range of the Boehringer Mannheim assay. In four
laboratories 213 serum samles were analysed for CEA
with the Abbott IMx assay and the Boehringer Mann-
heim. The correlation is represented in figure 5. The re-
gression equation was: y = 1.136 χ + 0.523 (BM = y
and IMx = x) (r = 0.967; p = < 1(T6).
Reference values
Reference values based on helathy subjects were deter^
mined using the Boehringer Mannheim assay. The re-
sults were compared with the value on the package in-
sert of the assays. Table 4 shows that all results obtained
CA 15-3 (ELSA CA 15-3) [kU/l]
Fig. 4 CA 15-3. Comparison of Enzymun-Test® CA 15-3 (y-axis)
with ELSA CA 15-3 (x-axis). The correlation is indicated by a
solid line in comparison with y = x.
20 30 40
CEA (IMx CEA) [kU/l]
50
Fig. 5 CEA. Comparison of Enzymun-Test® CEA (y-axis) with
IMx CEA (x-axis). The correlation is indicated by a solid line in
comparison with y = x.
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Tab. 4 Reference values for 7 tumour markers. 95th and 99th percentiles of previous experiments and





















































') values based on non-malignant lung diseases 2) values based on healthy subjects
in this study (with the exception of Cyfra 21-1) were
below the assigned values. The reference value of Cyfra
21-1 based on non-malignant lung diseases (8.8 μg/l) is
significantly higher than the value quoted on the pack-
age insert.
CA 125 in gynaecological diseases
The 95th percentile in healthy female blood donors
(N = 140) using Enzymun-Test® CA 125 II was 21.8
kU/1. This is substantially lower than the generally ac-
cepted reference level of 35 kU/1. Of 41 patients with
endometriosis, 28 (68%) had levels above 21.8 kU/1 and
25 patients (61%) had concentrations above 35 kU/1.
Levels of CA 125 II up to 295 kU/1 were recorded in
patients with endometriosis. In contrast, in patients with
benign ovarian cysts (N = 20), 7 (35%) had concentra-
tions above 21.8 kU/1 and only 2 (10%) had levels above
35 kU/1.
Sensitivity of tumour markers in
gastrointestinal cancer
In table 5 the 95% reference levels of CEA, CA 19-9
and CA 72-4 are presented as they were determined in
this study in healthy individuals (N = 1098) and benign
gastrointestinal diseases (N = 103). The sensitivity of
these markers at 95% specificity, as determined in this
study for normals and patients with benign disease, was
calculated in pre-operative samples of patients with co-
lon cancer, pancreatic cancer and gastric cancer. These
results are summarized in Tables 6a, b, and c.
Tab. 5 Reference values of Enzymun-Test® CEA, CA 19-9 and
CA 72-4 based on healthy subjects obtained in this study and val-
















In colon cancer, CEA is the most sensitive marker for
both reference groups: 59% and 44% respectively. The
difference in sensitivity with either CA 19-9 or CA 72-
4 is highly significant (p = 0.008 and ρ = 5.2 Χ 1(Γ7,
respectively). The combination of CEA with CA 19-9
increases the sensitivity to 70% using healthy individ-
uals as the reference group (p = 0.02). In comparison
with the benign gastrointestinal disease group a small
increase is seen by combining CEA with CA 19-9 or
CA 72-4. However, this is not significant. In pancreatic
cancer, CA 19-9 showed the highest sensitivity, com-
pared with both reference groups (78% and 62%, respec-
Tab. 6 Gastrointestinal cancers. The sensitivity was calculated
according to the cut-off based on healthy subjects obtained in this
study and the cut-off based on patients with benign gastrointestinal
diseases. The number expresses the number of values above the
cut-off; in ( ) the percentage elevated values is given.
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diseases, N = 103 CA 72-4
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tively with p-values ranging from 7.5 X 10 4 to 4.3
X 10~7). The small increase in sensitivity achieved by
combining CA 19-9 with either CEA or CA 72-4 is not
significant.
In gastric cancer, CA 19-9 showed the highest sensitiv-
ity (44%) compared with healthy individuals, whereas
CA 72-4 has the highest sensitivity (31%) compared
with the benign disease group. However, these differ-
ences in sensitivity between the three markers are not
significant. With healthy individuals as the control
group, the sensitivity is increased by combining CA 19-
9 with either CEA or CA 72-4 (p = 0.03 and p = 0.04,
respectively). However, there is no significant difference
between the combination CA 19-9 + CEA or CA 72-
4 + CEA. With the benign disease group as control,
sensitivity is highest in the combination CA 72-4 +
CEA but this is not significantly different from the sen-
sitivity of the CA 72-4 determination alone. In 74 out
of 110 serum samples from gastric cancer patients, stag-
ing was available (tab. 7). The sensitivity of all markers
in stage I and II cancer is very low, compared with the
healthy control group. When compared with the benign
disease group, only CA 19-9 showed elevated levels
(6/19) in stage II cancer. In stage III cancer the sensitiv-
ity of the three markers is the same for both reference
groups. In stage IV, CA 72-4 has the highest sensitivity
(59%) as compared with the benign disease group. This
is significant when compared with CA 19-9 (p = 0.04),
but not when compared with CEA. When the benign
disease group is taken as the reference group, only CA
72-4 is stage-dependent (stage III/IV: ρ = 0.04).
Discussion
Quality control and standardisation of tumour marker
tests is becoming increasingly important, since it is im-
portant, for both patients and physicians, to use the re-
Tab. 7 The number of patients with elevated levels of CEA, CA
19-9 and CA 72-4 in gastric cancer stage 1-IV according to the
reference is represented. Values based on healthy subjects obtained
in this study and on patients with benign gastrointestinal diseases.














































suits of these marker tests appropriately, and to avoid
uncritical overestimation or premature rejection of their
use (9-11). The trend toward increasing automation is
favorable with respect to reproducibility of test results.
Also our results from this multicentre study, using the
automatic ES 300 and ES 600 analysers, prove that
within a given method highly satisfactory results can be
obtained with tumour marker determinations. In 95% of
cases, the target intra-assay coefficient of variation of
less than 5% was achieved for all markers in serum sam-
ples with levels starting at the cut-off level and higher.
In 86% of the inter-assay determinations in the institutes
using low and high control samples, a target inter-assay
coefficient of variation of less than 10% was found (tabs.
1 and 2). Also the results of the interlafopratory survey
demonstrate the consistency of the test results of the
system used (tabs. 3 and 4; fig. 3). Linearity of the test
system was already reported to be highly satisfactory
(5).
However, it is obvious from figures 4 and 5 that the
determination of the same tumour marker using different
test systems is not well standardised, even when the
same monoclonal antibodies are used, as in the CA 15-
3 tests (12). The problem of standardisation increases
when different antibodies are used, as in the CEA test.
Of special clinical interest are the reference levels deter-
mined in different institutes compared with the values
given by the manufacturer in the package insert. In this
study, combining the tumour marker values of healthy
individuals as they were determined in 23 institutes, the
95 and 99 percentiles was somewhat lower than given
by the manufacturer of Enzymun-Test®. This is again
an indication that the system is highly reproducible in
different institutes. Only the reference limit of Cyfra
21.1 was found to be somewhat higher in healthy in-
dividuals, and this reference limit was definitely higher
when patients with benign king disesae were taken as
the reference group (in accordance with the manufactur-
er's insert). To find the correct cut-off in benign lung
diseases it will be necessary to use larger groups, includ-
ing a clear definition of diseases like chronic obstructive
lung disease, acute obstructive lung disease, inflamma-
tory lung disease etc. Therefore the sensitivity of
CYFRA 21.1 in lung cancer needs further investigation
(13).
CA 125 discriminated well between patients with endo-
metriosis and healthy female donors (14). In our study
using the second generation test of CA 125, the 95th
percentile of healthy female donors was distinctly lower
(21.8 kU/1) than reported for the original Centocor CA
125 version (35 kU/1).
CEA has long been used in colorectal cancer, and more
recently the determination of CA 19-9 was applied in
pancreatic cancer (15-17). The contribution of the new
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marker CA 72-4 has been discussed, and its application
in gastric cancer has been proposed (18—26). We com-
pared the results of these three markers in gastrointesti-
nal cancers in comparison with the cut-off in healthy
individuals and in benign gastrointestinal diseases. As
expected, a higher cut-off was determined for the three
markers using as the reference group patients with be-
nign gastrointestinal diseases (tab. 5). In particular, CA
19-9 showed a much higher cut-off (75 kU/1 versus 21.5
kU/1) for this reference group. In colorectal cancer (in-
cluding 226 patients with all preoperative stages) CEA
appeared to be still the marker of choice, irrespective of
the reference group. By combining marker results —
where one or the other should be elevated — the speci-
ficity was decreased. The increase in sensitivity was
only significant when the combination of CEA and CA
19-9 was used, as compared with the normal cut-off.
This is caused by the low specificity of CA 19-9 in be-
nign gastrointestinal disease. In pancreatic cancer (63
patients) CA 19-9 was the most sensitive marker, as al-
ready reported (15 —17). No significant increase in sen-
sitivity is obtained by combining CA 19-9 and CEA de-
terminations or CA 19-9 and CA 72-4. It has been re-
ported that CA 72-4 has a high sensitivity in gastric
cancer (18, 19). Others, in rather small series, could not
confirm this observation, but they used different cut-off
levels, i. e. 4 kU/1 (20) and 6 kU/1 (21). In a larger series,
Wobbes et al. used a cut-off of 3 kU/1 and estimated a
sensitivity for both CA 72-4 and CA 19-9 (cut-off 37
kU/1) of 34% in a group of 94 patients with gastric carci-
noma (22). In our study, comprising 110 patients, we
determined the sensitivity of CA 72-4, CA 19-9 and
CEA in comparison with the 95% reference level in nor-
mals and in benign gastrointestinal disease from our
own investigations. For CEA these reference levels were
somewhat lower than is generally accepted (3.4 g/l in
normals and 6.2 g/l in benign disease). For CA 19-9
the reference level in normals was lower (21.5 kU/1) but
in benign disease we found a high reference level of 75
kU/1. For CA 72-4 the reference level in normals was
4.5 kU/1 and in benign disease 8.9 kU/1. Therefore the
sensitivity of these markers does not compare very well
with that reported earlier (20^22). However, the pro-
blem of standardisation of test results using different test
systems has to be kept in mind. Most of the investiga-
tions with CA 72-4 and CA 19-9 were performed using
the Centocor IRMA test. In comparison with healthy
individuals CA 19-9 showed the highest sensitivity
(44%), but compared with the benign disease group CA
72-4 was more sensitive (31%). This can be explained
by the high reference level of CA 19-9 in the benign
disease group. In our calculations the differences in sen-
sitivity were not significant. However, significance was
not calculated in the earlier reports (20—22). Besides,
the cut-off levels chosen in these studies for the different
markers resulted in different specificities of the markers.
In a study including 161 gastric patients, divided accord-
ing to stage, Guadagni et al. found CA 72-4 to be more
sensitive (42.2%) than CA 19-9 (32.3) or CEA (24.2%)
in the overall group (23). The highest sensitivity was
reported in stage IV (including metastatic disease): CA
72-4: 58%; CA 19-9: 44.2% and CEA: 39.5%. This is
in agreement with our results where a sensitivity for CA
72-4 of 59% was determined in stage IV, which was
higher than the sensitivity of CA 19-9 (34%) using the
benign disease group as the control. They also stated
that the sensitivity of CA 72-4 was stage-dependent, as
we also found in our study. We also confirmed that the
sensitivity could be increased by combining CA 72-4
and CA 19-9 (in our study only when the healthy con-
trols were taken as the reference group). Other recent
data in large patient groups indicated CA 72-4 to be the
marker of choice using a cut-off level for CA 72-4 of
3.9 kU/1 at 95% specificity in a group of patients with
benign disease of the gastrointestinal tract, including pa-
tients with benign liver disease (24). However, at this
95% specificity the cut-off level for CA 19-9 was very
high: 166 kU/1. This could explain the relatively high
sensitivity of CA 72-4 (36%) compared with CA 19-9
(21%). At the time of local relapse, or occurrence of
distant metastases, the sensitivity of CA 72-4 was 56%
(56%) and of CA 19-9 18% (28%). Gartner et al. could
not confirm this high sensitivity of CA 72-4 compared
with CA 19-9 (25). But in this study the cut-off value
for CA 72-4 was 6.8 kU/1 and for CA 19-9 37 kU/1. Saß
et al. calculated again a high sensitivity for CA 72-4
using different cut-off levels for CA 72-4 i. e. 2.5 kU/1
and 10 kU/1 (26). Very few patients with benign gastro-
intestinal disease showed levels above 10 kU/1. Probably
the reference level of CA 19-9 was fixed at 37 kU/1.
They also found CA 72-4 to be clearly stage-dependent,
but determined a sensitivity for CA 72-4 of 31% in stage
I gastric cancer versus 88% in stage IV.
In conclusion, in the present study we compared the sen-
sitivity of the markers CEA, CA 19-9 and CA 72-4 in
gastrointestinal cancer at 95% specificity, using cut-off
levels of healthy individuals and patients with benign
gastrointestinal disease, according to earlier recommen-
dations by the working group 'Quality control and Stan-
dardization of Tumour Marker Tests' under the auspices
of the Hamburg Symposia on Tumour Markers (27). The
reference data were obtained in the study and not just
taken from the test package inserts. CEA is still the
marker of choice in colorectal cancer as is CA 19-9 in
pancreatic cancer. In these two types of cancer no
increase in sensitivity was registered by combining
markers when the benign disease group was taken as the
reference group. Therefore it seems sufficient to deter-
mine only one marker in these disease groups. In gastric
cancer no definite conclusion can be given. The advan-
tage of CA 72-4 could be that the marker is stage-depen-
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dent and has the highest sensitivity in advanced dis-
ease (stage IV) as compared with the benign disease
group.
The intra-assay precision, inter-assay precision and in-
terlaboratory survey all proved that Enzymun-Test®
gave reliable results for tumour marker tests. From the
analytical point of view, this fulfills a further require-
ment of the previously mentioned working group (27).
Recently, at the Bergmeier conference under the aus-
pices of IFCC, these requirements were discussed for
several tumour markers (9, 12). We believe that in the
near future unequivocal analysis and reporting of tu-
mour marker data will be a necessity in order to
supply clinicians with relevant information for the care
of oncological patients.
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Report on the Symposium1)
"Drug Effects in Clinical Chemistry Methods"
held on December 8, 1995 in Penzberg, Bavaria, Germany
Josef Breuer
Marienhospital Gelsenkirchen, Gelsenkirchen, Germany
Summary: The aim of the symposium was to establish a list of 20—30 drugs and to determine test concentrations
(at therapeutic levels and above) that would indicate interference to clinical chemistry methods in serum and plasma.
The following agents were chosen:
Acetaminophen, Acetylcysteine, Acetylsalicylic acid, Ampicillin, Ascorbic acid, Ca-Dobesilate, Cefoxitin, Cyclo-
sporine, Heparin, Ibuprofen, Intralipid, Levodopa, Methyldopa, Metronidazole, Phenylbutazone, Rifampicin, Tetra-
cycline, Theophylline.
Introduction
On December 8, 1995, the following experts came to-
gether in Penzberg, Bavaria, Germany, to discuss drug
effects on clinical chemistry methods:
/. Breuer, Gelsenkirchen, Germany
R. Galimany, Barcelona, Spain
R Gerthoux, Milano, Italy
P. Koller, Mannheim, Germany
W. Mühe, Gelsenkirchen, Germany
J. Salway, Surrey, Great Britain
R. Scholer, Basel, Switzerland
O. Sonntag, Illkirch, France
N. Tryding, Kristianstad, Sweden
The aim of this symposium was to establish a drug inter-
ference list and testing levels at which one may deter-
mine interference to clinical chemistry methods in se-
Tab. 1 Drugs and concentrations to be tested for drug interferences in serum/plasma












































































* c\ drug concentration above therapeutic level
b c2 drug concentration at therapeutic level
!) The symposium was generously supported by Boehringer
Mannheim.
A further symposium is scheduled to make a list of drugs for in
vitro testing in urine.
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rum and plasma and which can be tested in vitro. To
prepare for the discussion, everyone had to send a list
of his "favorite" drugs to the organizers. Additional lists
were also sent by G. Siest, Nancy, France and H. Sine,
Indianapolis, USA.
Results and Discussion
At the beginning of the meeting the following criteria
were examined in order to select a valid list from the
above mentioned "favorite" lists:
— Typical (high) serum concentration
— Typical test interference on clinical chemistry meth-
ods
— How often is the drug used?
— Relevance in vivo
- Drugs absorbing light at clinical chemistry methods
wavelengths
Further background information utilized during the dis-
cussion was the 7th edition of the book by Nils Tryding
(1) and the proposed Guideline Interference Testing in
clinical chemistry by NCCLS (2).
The outcome of the symposium is summarized in
table L
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